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FK506 (Fi<) is a novel lmmunosuppressl ve arug lsolatea from 
Streptomyces tsukubaensis. Its 1n vitro effect on lymphocyte 
proliferation is several hundred fold greater than that of 
Cyclosporine A (CsA). Studies ..... ere conducted on the inhibitory 
effect of combinations of FK and CsA on lymphocyte proliferation 
in vitro. The secondary proliferative response (PLT) of 
alloreactive T cells ..... as significantly inhibited by a combination 
of 0.06 nglml of FK and 1 nglml CsA. At these low 
concentrations, these drugs were ineffective. The synergistic 
e f fee t bet wee n F K and C sAw a s a Iso de 0, 0 n s t rat edt h r 0 ugh 
sequential exposure of alloreactive lymphocytes to Fi< followed by 
CsA. Pretreatment of IL-2 expanded alloreactive cells with Fi< 
yielded cell cultures whose PLT activity ..... as considerably more 
sensitive to low doses of CsA than control cells or CsA 
pretreated cells. These findings provide evidence for a 
synergism between the inununosuppressive effects of Fi< and CsA. 
The combination of low dose FK plus CsA inununosuppression may 
benefit organ transplant outcome. 
Recent studies have described a new, potent 
immunosuppressive drug FK 506 which induces considerable 
prolongation of allograft survival (1,2,3). Fi< is isolated from 
Streptomyces tsukubaensis in Osaka, Japan. Its molecular 
structure resembles the macrolide family with a molecular weight 
of 822 daltons (4). The inununosuppressive effect of Fi< can be 
demonstrated in primary mixed lymphocyte reaction (MLR), and in 
secondary proliferation of al10reactive T cells generated from 
MLR or propagated from organ transplant biopsies (5,6). 
Studies on lymphocyte proliferat10n 1n prlmary MLR have 
previously shown that inhibition was achieved with doses of Fl< 
that were several hundred fold lower than those of CsA (5,6). An 
example of the difference between Fl< and CsA is illustrated in 
Table 1. Significant inhibition (>70\) of the alloreactive 
response, measu red in pr imed 1 ymphocy te tes t ( PLT), of ali ver 
biopsy propagated lymphocyte culture was achieved with a low dose 
of 0.25 ng/ml Fl<. On the contrary, a 200 fold higher 
concentration of CsA was necessary to obtain the same level of 
inhibition. In vivo studies have shown a similarly potent effect 
of Fl< on the prolongation of transplant survival in experimental 
animals (7-9). 
Polypharmaceutical therapy is currently widely used in organ 
transplantation to avoid side effects associated with high doses 
of a single agent. Studies have been conducted to determine in 
vitro synergism between Fl< and CsA. Our first approach was to 
add to lymphocyte cultures low doses of these drug combinations. 
As shown in Figure 1, the combination of 0.06 nglml Fl< and 10 
ng/m1 of CsA induced a significant inhibition (40\) of the PLT 
reactivity of liver biopsy grown cells. On the other hand 
neither drug was effective at these low doses. In addition, a 10 
fold lower dose of CsA (1 ng/ml) 0.06 ng/ml of fK induced a 
significant PLT inhibition indicating that fK acts 
synergistically with a relatively wide dose range of CsA (Figure 
1). In contrast, a two-fold reduction of the fK dose (to 0.03 
ng/m1) added to 10 ng/ml of CsA greatly diminished the 
synergistic inhibitory effect between these drugs (10,11). 
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The second approach to study the synergistic effect between 
these two drugs was through sequential exposure of alloreactive 
lymphocytes to FK followed by CsA. Because FK and CsA have no 
effect on IL2 induced proliferation of activated T cells (10), 
experiments were set up whereby heart transplant biopsy grown 
lymphocytes were expanded in IL2 in the presence of various 
concentrations of FK (0.1 uglml and 0.01 ug/ml) or CsA (10 
ug/ml) . After four days 1n culture, these pretreated cells 
showed similar PLT reactivity and IL-2 responsiveness as 
untreated control cultures. On the other hand, FK pret reated 
cultures showed increased CsA sensitivity when tested 1n PLT 
(Table 2). For instance, the PLT response of alloreactive T 
cells pretreated with 0.1 nglml FK was inhibited by 78\ with a 
low dose of 0.05 nglml of CsA. On the other hand, pretreatment 
with 10 nglml of CsA did not effect the CsA sensitivity of a 
subsequent PLT (Table 2). 
These findings of a synergism between FK and CsA have an 
important clinical application in that low doses of these drug 
combinations may have less adverse side effect but are still 
effective in increasing transplant survival. Indeed, Todo and 
his colleagues, using the experimental models of heterotopic 
heart transplantation in rats and renal allografts in dogs, have 
recently demonstrated that the most efficient immunosuppressive 
protocols are combinations of low doses of FK with 
subtherapeutical doses of CsA and prednisone (7). 
The mechanism of the synergism between FK and CsA is 
unknown. Preliminary observations at our institution have shown, 
that FK enhances CsA uptake by peripheral blood lymphocytes (12). 
It is possible that the synergism between FK and CsA might be 
related to lymphocyte membrane binding of these drugs. 
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FIGURE 1 
Synergism between the immunosuppressive effects of FK506 and 
CsA. The donor-specific PLT reactivity of· liver biopsy 
propagated lymphocyte culture was tested in the presence of 
combinations of low doses of fK (0.06 ng/ml) and CsA (10 ng/ml or 
1 ng/ml). 
